Pharmaceutical News

RSS

Oral semaglutide improves blood sugar, weight, and liver markers in real-world diabetes care

A nationwide Finnish registry study of 7,249 GLP-1RA-naïve adults with type 2 diabetes found that once-daily oral semaglutide was associated with 12-month improvements in HbA1c, body weight, lipid markers, and ALT.

11 Jun 2026

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.

11 Jun 2026

FDA accepts immunotherapy drug for review in colon cancer treatment

The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has accepted for review Genentech's supplemental Biologic License Application for their immunotherapy drug atezolizumab (Tecentriq®) for the treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR).

11 Jun 2026

Intravenous statins during heart attack reduce cardiac muscle damage

Reducing the damage sustained by the heart during a myocardial infarction remains one of the major challenges in cardiology, even when the blocked coronary artery is reopened in a timely manner.

11 Jun 2026

GLP-1 medicines may cut clot-related risks in chronically inflamed patients

In a target trial emulation using OneFlorida+ electronic health record data, GLP-1 receptor agonist use in adults with obesity and autoimmune disease was linked to lower hazards of pulmonary embolism, venous thromboembolism, stroke/TIA, emergency department visits, and all-cause mortality.

10 Jun 2026

Apitegromab helps tirzepatide users lose fat while preserving lean mass

A phase 2 trial found that apitegromab plus tirzepatide reduced lean body mass loss by 1.9 kg compared with tirzepatide plus placebo after 24 weeks, while overall weight loss remained similar.

9 Jun 2026

Obesity drug mazdutide reduces weight and waist size in major trial

Once-weekly 9 mg mazdutide produced clinically meaningful weight loss in Chinese adults with obesity, reducing body weight by 16.65% after 60 weeks versus 1.50% with placebo. The phase 3 GLORY-2 trial also found improvements in waist circumference, systolic blood pressure, and lipid markers, but gastrointestinal adverse events were common.

9 Jun 2026

New geroscience initiative aims to accelerate anti‑aging therapies

Albert Einstein College of Medicine has launched the Batia and Idan Ofer program for Validation of Interventions Targeting Aging and Longevity (BIO-VITAL), a new initiative designed to help biotechnology and pharmaceutical companies advance therapies that target the biology of aging.

9 Jun 2026

Pharmacist prescribing could unlock $1 billion in savings; free 10 million GP visits and prevent 30,000 hospitalizations annually

New national modelling identifies pharmacist prescribing as a practical, scalable reform to improve access to care at a time when GP workforce shortages are projected to worsen.

9 Jun 2026

GLP-1 users say the drugs quiet food noise but do not replace lifestyle change

A qualitative study of 30 US adults found that GLP-1 receptor agonists often reduced “food noise,” psychological hunger, and appetite, helping patients feel more able to make deliberate lifestyle changes.

8 Jun 2026

Weight loss drugs linked to lower risk of alcohol, opioid, nicotine and cocaine use disorders

A new study led by researchers at The University of Texas at El Paso found that use of weight loss drugs like Ozempic and other GLP-1s is associated with a lower risk of developing alcohol, opioid, nicotine and cocaine use disorders.

8 Jun 2026

Antibiotic by-products in waterways continue promoting bacterial resistance

Antibiotics continue to drive resistance to bacteria, even after they are broken down in wastewater treatment plants and discharged into rivers and seas, new research published on World Oceans Day has shown for the first time.

8 Jun 2026

Diabetes drug dramatically lowers heart failure risk in genetic carriers

Rare genetic variants known to cause cardiomyopathy, an inherited cause of a weak heart, can increase the risk of patients developing heart failure.

8 Jun 2026

GLP-1 therapies linked to fewer complications in adults with both obesity and autoimmune disease

Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) medication had lower rates of emergency department visits and were less likely to experience serious cardiac events, such as stroke, pulmonary embolism or death when compared to similar adults who were not taking these medications, according to new research published today in the Journal of the American Heart Association, an open-access, peer-reviewed journal of the American Heart Association.

7 Jun 2026

Researchers challenge the traditional understanding of how histone deacetylase inhibitors function

Researchers at Baylor College of Medicine and collaborating institutions are challenging the traditional understanding of how cancer drugs called histone deacetylase (HDAC) inhibitors function.

5 Jun 2026

Flu drugs may reduce cognitive decline in people with HIV

A class of flu drugs may reduce cognitive decline and premature aging in people living with chronic viral infection, reports a new study led by Northwestern University that began with blood samples from people with HIV and extended into preclinical drug trials.

5 Jun 2026

Histamine boost helps the brain remember, decide, and learn from loss

Pitolisant, a histamine H3 receptor inverse agonist, improved recognition memory, working memory performance, and reinforcement learning in healthy adults. The findings suggest that histamine helps shape how the brain stabilizes new memories, accumulates evidence for decisions, and avoids overreacting to negative outcomes.

3 Jun 2026

Antidepressant drugs detected at potentially harmful levels in waterways

Depression, anxiety and sleep disorders are among the conditions often treated with antidepressant drugs. Yet, up to 90% of these drugs pass through the body into wastewater.

3 Jun 2026

Could GLP-1 drugs help prevent breast cancer? New study points to a possible link

A large retrospective cohort study of 111,646 overweight or obese women found that GLP-1 agonist exposure was associated with lower breast cancer incidence. After propensity-score matching, GLP-1 exposure was linked to nearly 30% lower odds of breast cancer, but the authors stress that randomized trials are needed before these drugs can be considered for prevention.

3 Jun 2026

Aspirin use may help unmask early asymptomatic bladder cancer

The presence of blood cells in urine is a sign of bladder cancer. Because aspirin blocks platelets from forming harmful blood clots, the medication can cause mild bleeding or worsen existing bleeding in the urinary tract.

3 Jun 2026